Table 4.
Multivariable analysis of progression-free and overall survival according to occurrence of irAE in NSCLC.
| PFS with 14-week landmark | HR | P-value | 95%-CI |
|---|---|---|---|
| IrAE occurrence | 0.65 | 0.005 | 0.48–0.88 |
| PD-L1 TPS (<1, 1–49, 50+) | 0.74 | 0.002 | 0.61–0.90 |
| NLR (≥5, <5) | 0.99 | 0.95 | 0.75–1.29 |
| Treatment line | 1.18 | 0.06 | 1.00–1.39 |
| Treatment type1 | 1.20 | 0.36 | 0.83–1.72 |
| ECOG PS | 1.14 | 0.30 | 0.89–1.46 |
| OS with 14-week landmark | HR | P-value | 95%-CI |
| IrAE occurrence | 0.38 | <0.001 | 0.27–0.56 |
| PD-L1 TPS (<1, 1–49, 50+) | 0.78 | 0.008 | 0.66–0.94 |
| NLR (>5, <5) | 1.37 | 0.01 | 1.07–1.76 |
| Treatment line | 1.15 | 0.06 | 0.99–1.32 |
| Treatment type1 | 0.78 | 0.20 | 0.54–1.14 |
| ECOG PS | 1.30 | 0.03 | 1.02–1.65 |
The association of irAE and other variables with progression-free (PFS) and overall survival (OS) was analyzed using a multivariable Cox regression 14-week landmark analysis. Statistically significant results have been highlighted in bold.
PFS, progression-free survival; OS, overall survival; HR, hazard ratio; 95% CI, 95% confidence interval; irAE, immune related adverse events; ECOG PS, Eastern Cooperative Oncology Group Performance Status; IO, immunotherapy; PD-L1 TPS, Programmed Death Ligand 1 Tumor Proportion Score (%); NLR, neutrophil-to-lymphocyte ratio.
1chemoimmunotherapy vs. IO-monotherapy.